[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK0494405T3 - Anvendelse af thiazolidin-4-carboxylatderivater til behandling af lungesygdomme - Google Patents

Anvendelse af thiazolidin-4-carboxylatderivater til behandling af lungesygdomme

Info

Publication number
DK0494405T3
DK0494405T3 DK91121524.2T DK91121524T DK0494405T3 DK 0494405 T3 DK0494405 T3 DK 0494405T3 DK 91121524 T DK91121524 T DK 91121524T DK 0494405 T3 DK0494405 T3 DK 0494405T3
Authority
DK
Denmark
Prior art keywords
treatment
thiazolidine
lung disease
carboxylate derivatives
carboxylate
Prior art date
Application number
DK91121524.2T
Other languages
English (en)
Inventor
Dennis Goldberg
Original Assignee
Transcend Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24563439&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0494405(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Transcend Therapeutics Inc filed Critical Transcend Therapeutics Inc
Application granted granted Critical
Publication of DK0494405T3 publication Critical patent/DK0494405T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK91121524.2T 1991-01-10 1992-01-01 Anvendelse af thiazolidin-4-carboxylatderivater til behandling af lungesygdomme DK0494405T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63927591A 1991-01-10 1991-01-10

Publications (1)

Publication Number Publication Date
DK0494405T3 true DK0494405T3 (da) 1996-11-18

Family

ID=24563439

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91121524.2T DK0494405T3 (da) 1991-01-10 1992-01-01 Anvendelse af thiazolidin-4-carboxylatderivater til behandling af lungesygdomme

Country Status (10)

Country Link
US (1) US5824693A (da)
EP (2) EP0715853A1 (da)
JP (2) JP2969236B2 (da)
AT (1) ATE144142T1 (da)
AU (2) AU1006492A (da)
CA (1) CA2058793A1 (da)
DE (1) DE69214467T3 (da)
DK (1) DK0494405T3 (da)
ES (1) ES2092539T3 (da)
GR (1) GR3021890T3 (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631234A (en) * 1991-04-15 1997-05-20 Teijin Limited Method for treating ischemia-reperfusion tissue injury
FR2763845B1 (fr) 1997-05-30 2003-04-18 Centre Nat Rech Scient Produits anti-cancereux pour le traitement de la mucoviscidose
US6197749B1 (en) 1997-10-29 2001-03-06 Ajinomoto Co., Inc. Method of suppressing immune responses by reducing intracellular content of glutathione in macrophages and monocytes
EP1004302A3 (en) * 1998-10-29 2003-06-04 Ajinomoto Co., Inc. Immunomodulator
CA2419845A1 (en) 1999-08-17 2002-02-22 Phyllis G. Paterson Improved treatment for acute physical insult to the central nervous system
US7179791B2 (en) * 2001-01-11 2007-02-20 Duke University Inhibiting GS-FDH to modulate NO bioactivity
WO2002069964A1 (en) 2001-03-05 2002-09-12 Ernest Stephen P Enteral formulation
KR100478536B1 (ko) * 2002-10-14 2005-03-24 주식회사 에이.비.아이 Ｌ-2-옥소씨아졸리딘-4-카르복실산 또는 그 염을유효성분으로 함유하는 천식 치료용 약제학적 조성물
US20040229815A1 (en) * 2003-01-03 2004-11-18 Nagasawa Herbert T. Methods for reducing oxidative stress in a cell with a sulfhydryl protected glutathione prodrug
ATE377060T1 (de) 2003-02-21 2007-11-15 Metabolix Inc Pha-klebstoffe
US7781539B2 (en) 2003-02-21 2010-08-24 Metabolix Inc. PHA blends
DE602004016563D1 (de) 2003-12-30 2008-10-23 Metabolix Inc Nukleierungsmittel
CA2620123C (en) * 2005-08-24 2011-11-22 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating and monitoring inflammation and redox imbalance in cystic fibrosis
US20090192227A1 (en) * 2005-08-24 2009-07-30 Rabindra Tirouvanziam N-Acetylcysteine Compositions and Methods for Treating Acute Exacerbations of Inflammatory Lung Disease
US7526715B2 (en) 2005-10-17 2009-04-28 Ramot At Tel Aviv University Ltd. Probabilistic error correction in multi-bit-per-cell flash memory
US20070255406A1 (en) * 2006-04-27 2007-11-01 Sdgi Holdings, Inc. Devices, apparatus, and methods for bilateral approach to disc augmentation
CN109054254B (zh) 2012-08-17 2021-02-02 Cj第一制糖株式会社 用于聚合物共混物的生物基橡胶改性剂
CA3153463A1 (en) 2012-10-29 2014-05-08 The University Of North Carolina At Chapel Hill Methods and compositions for treating mucosal tissue disorders
US20140234397A1 (en) * 2013-02-15 2014-08-21 Lou Ann Brown Treatment of klebsiella pneumoniae with liposomally formulated glutathione
US10669417B2 (en) 2013-05-30 2020-06-02 Cj Cheiljedang Corporation Recyclate blends
CN110198728A (zh) 2016-11-17 2019-09-03 莱诺翁股份有限公司 用谷胱甘肽组合物治疗呼吸道疾病和感染
EP4473976A3 (en) 2017-11-17 2025-03-12 Renovion, Inc. Stable ascorbic acid compositions and methods of using the same
CN113797230B (zh) * 2020-06-12 2025-01-28 上海萨美细胞技术有限公司 无细胞脂肪提取液对肺部疾病的治疗用途
CN118632703A (zh) 2022-01-04 2024-09-10 莱诺翁股份有限公司 含有谷胱甘肽盐的水性溶液
WO2025012197A1 (en) 2023-07-10 2025-01-16 Biomedica Foscama Industria Chimico-Farmaceutica S.P.A. Glutathione for use in the prevention and/or treatment of cardiovascular and respiratory complications concomitant with and/or consequent to pneumonia

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2712202A (en) * 1954-06-08 1955-07-05 Univ Alabama Method of treating tree diseases
DE1767335A1 (de) * 1968-04-27 1971-09-02 Bayer Ag Anaesthetikum fuer Tiere
US3755578A (en) * 1969-06-06 1973-08-28 Pfizer Thiazoline and 5,6-dihydro-4h-1,3-thiazine anti-plant-viral agents
DE2141765A1 (de) * 1971-08-20 1973-03-01 Henkel & Cie Gmbh 4-chlor-4-thiazolin-2-one und verfahren zu deren herstellung
FR2296428A1 (fr) * 1975-01-03 1976-07-30 Baignes Ste Radegonde Laiterie Composition de proteines a usage dietetique et therapeutique chez le nourrisson, l'enfant et l'adulte
JPS53119866A (en) * 1977-03-25 1978-10-19 Yoshitomi Pharmaceut Ind Ltd 5-aryloxy-oxazoleakanoic acid derivatives and their preparation
EP0002978B1 (fr) * 1977-12-29 1982-10-06 Synthelabo Dérivés de thiazolidinedione-2,4, leur préparation et leur application en thérapeutique
US4384001A (en) * 1978-12-21 1983-05-17 Gosalvez Mario Treatment of tumors with thiazolidine-4-carboxylic acid
US4338315A (en) * 1979-11-14 1982-07-06 Eli Lilly And Company Antiviral method employing thiazinyl benzimidazole derivatives
US4665082A (en) * 1981-02-11 1987-05-12 Cornell Research Foundation Cysteine delivery system
US4438124A (en) * 1981-02-11 1984-03-20 Cornell Research Foundation, Inc. Cysteine delivery system
US4647571A (en) * 1981-02-11 1987-03-03 Cornell Research Foundation Cysteine delivery composition
US4335210A (en) * 1981-02-11 1982-06-15 Cornell Research Foundation Method of producing L-cysteine
US4434158A (en) * 1981-02-11 1984-02-28 Cornell Research Foundation Cysteine delivery system
JPS57200373A (en) * 1981-06-04 1982-12-08 Taisho Pharmaceut Co Ltd Thiazolidine derivative
US4420479A (en) * 1982-04-08 1983-12-13 Eli Lilly And Company Olefinic benzimidazoles, formulations, and antiviral methods
DE3317000C2 (de) * 1983-05-10 1986-09-25 Gödecke AG, 1000 Berlin 4-Oxo-thiazolidin-2-yliden-acetamid-derivate, Verfahren zu deren Herstellung und deren Verwendung bei der Bekämpfung von durch das Zentralnervensystem bedingten Konvulsionen
US4879370A (en) * 1983-12-02 1989-11-07 Cornell Research Foundation, Inc. Glutathione delivery system
US4752618A (en) * 1984-07-12 1988-06-21 New England Deaconess Hospital Method of minimizing efects of infection through diet
US4647453A (en) * 1984-10-18 1987-03-03 Peritain, Ltd. Treatment for tissue degenerative inflammatory disease
US4710489A (en) * 1985-04-22 1987-12-01 Cornell Research Foundation, Inc. Glutathione delivery system
HU200177B (en) * 1985-06-18 1990-04-28 Biogal Gyogyszergyar Process for producing thiazolidinecarboxylic acids and pharmaceutical compositions comprising such compounds
EP0218900B1 (en) * 1985-09-10 1992-01-22 Research Corporation Technologies, Inc. Osmotic agents for peritoneal dialysis
US4780475A (en) * 1986-02-03 1988-10-25 Cerra Frank B Preparation for the prevention of catabolism
JPS63152325A (ja) * 1986-08-20 1988-06-24 Yamanouchi Pharmaceut Co Ltd 脳虚血症予防治療剤
IT1202426B (it) * 1987-01-26 1989-02-09 Poli Ind Chimica Spa Derivato di acido tiazolidin-4-carbossilico,sua preparazione e composizioni farmaceutiche che lo contengono
US5053387A (en) * 1987-02-20 1991-10-01 Shriners Hospitals For Crippled Children Omega-3 fatty acids in traumatic injury treatment
US4868114A (en) * 1987-08-05 1989-09-19 Regents Of The University Of Minnesota Method for elevating glutathione levels
EP0306228B1 (en) * 1987-09-04 1999-11-17 Beecham Group Plc Substituted thiazolidinedione derivatives
US4968671A (en) * 1987-11-26 1990-11-06 Yamanouchi Pharmaceutical Co., Ltd. Therapeutic agents for ischemic heart diseases
US4791125A (en) * 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
US4798835A (en) * 1987-12-02 1989-01-17 Pfizer Inc. dl-5-[(2-benzyl-3,4-dihydro-2H-benzopyran-6-yl)methyl]thiazolidine-2,4-dione as an anti-atherosclerosis agent
EP0327263B1 (en) * 1988-01-29 1994-09-07 PROCTOR, Peter H. Hair growth stimulation with nitroxide and other radicals
IE891173L (en) * 1988-04-18 1989-10-18 Univ Utrecht Composition for promoting hair growth in androgenetic¹alopecia and method thereof
DE3816603A1 (de) * 1988-05-16 1989-11-30 Behringwerke Ag Verwendung des thiazol-derivates tiprotimod zur herstellung eines mittels zur therapie von virusinfektionen
US5055446A (en) * 1988-10-21 1991-10-08 University Of Cincinnati Method to improve survival of patients during sepsis by diet composition
EP0373002B1 (en) * 1988-12-09 1995-03-01 Allergan, Inc Use of 2-substituted-thiazolidine-4-carboxylic acids for treatment of cataract
CA1338682C (en) * 1988-12-23 1996-10-29 Gustavo Bounous Biologically active undenatured whey protein concentrate as food supplement
GB8918709D0 (en) * 1989-08-16 1989-09-27 Unilever Plc Cosmetic composition
US5158883A (en) * 1989-09-13 1992-10-27 Cornell Research Foundation, Inc. Method of using aminoarginine to block nitric oxide formation in vitro
US5028627A (en) * 1989-09-13 1991-07-02 Cornell Research Foundation, Inc. Method of using arginine derivatives to inhibit systemic hypotension associated with nitric oxide production or endothelial derived relaxing factor
AU7675891A (en) * 1990-03-28 1991-10-21 Atif M Hussein Methods for protecting against chemotherapy-induced hair loss
US5089268A (en) * 1990-05-02 1992-02-18 Katz David P Egg phosphatide lipid emulsions altered for a specific therapeutic fatty acid composition
US5095027A (en) * 1991-02-28 1992-03-10 Clintec Nutrition Co. Method for treating reperfusion injury employing L-2-oxothiazolidine-4-carboxylic acid
SE9103572D0 (sv) * 1991-11-29 1991-11-29 Astra Ab Organic salts of n,n'-diacetyl cystine
US5214062A (en) * 1992-04-08 1993-05-25 Clintec Nutrition Co. Method and composition for treating immune disorders, inflammation and chronic infections
US5208249A (en) * 1992-08-20 1993-05-04 Clintec Nutrition Co. Method for stimulating intracellular synthesis of glutathione using esters of L-2-oxothiazolidine-4-carboxylate

Also Published As

Publication number Publication date
JPH08319242A (ja) 1996-12-03
ATE144142T1 (de) 1996-11-15
EP0715853A1 (en) 1996-06-12
AU1006492A (en) 1992-07-16
ES2092539T3 (es) 1996-12-01
DE69214467T3 (de) 2000-09-28
JPH1053523A (ja) 1998-02-24
JP2969236B2 (ja) 1999-11-02
DE69214467T2 (de) 1997-04-30
EP0494405A2 (en) 1992-07-15
EP0494405B2 (en) 2000-04-19
AU7912194A (en) 1995-02-16
US5824693A (en) 1998-10-20
EP0494405B1 (en) 1996-10-16
EP0494405A3 (en) 1992-10-28
DE69214467D1 (de) 1996-11-21
GR3021890T3 (en) 1997-03-31
AU688803B2 (en) 1998-03-19
CA2058793A1 (en) 1992-07-11

Similar Documents

Publication Publication Date Title
DK0494405T3 (da) Anvendelse af thiazolidin-4-carboxylatderivater til behandling af lungesygdomme
DK0416951T3 (da) Lægemidler indeholdende salmeterol og fluticason
FI862011A0 (fi) Terapeutiska nukleosider.
ATE120644T1 (de) Verwendung von 1,3-oxathiolanalogen von nukleosiden zur herstellung eines arzneimittels zur behandlung von hepatitis-b.
ATE213946T1 (de) Formoterol und budesonide enthaltende zusammensetzung
DE69419755D1 (de) Chemische verbindungen mit pde-iv inhibitierende wirkung
ES2113413T3 (es) Derivados antiviricos del acido 2-desoxi-2,3-didehidro alfa-d-neuraminico 4 substituido.
DE59102210D1 (de) Galanthemin enthaltende pharmazeutische Formulierung zur Behandlung des Alkoholismus.
NO910213D0 (no) Fremgangsmaate for fremstilling av orale legemiddelformer av pimobendan.
ATE86491T1 (de) Verwendung von fluticasonpropionat zur herstellung eines praeparats zur behandlung von darmerkrankungen.
ES2096215T3 (es) Tucaresol como agente inmunopotenciador.
DK0416950T3 (da) Medikamenter
ATE185973T1 (de) Verwendung von humanem atrio-natriuretischem peptid zur herstellung eines medikaments zur behandlung des atemunwohlseinsyndroms bei erwachsenen
ES2179832T3 (es) Formas de administracion orales con contenido en flupirtina solida, con liberacion controlada del principio activo.
ATE121934T1 (de) Pharmazeutische klistierzubereitung.
SE8903764D0 (sv) Lung protection agents
CHO et al. Incidence and risk factors in retinopathy of prematurity
ITMI911845A1 (it) Uso dei derivati dell'acido benzimidazolin-2-oxo-1-carbossilico.
ATE145333T1 (de) Hirudin enthaltende orale arzneimittel
IL98199A (en) Pharmaceutical compositions containing a derivative of substituted l-valyl-l-prolinamide